Na ọgwụgwọ ọrịa shuga, insulin bụ otu n'ime ọgwụ kachasị dị irè maka ịchịkwa shuga ọbara.Ndị ọrịa nwere ụdị ọrịa shuga 1 na-achọkarị ịgba ọgwụ insulin ogologo ndụ ha niile, ndị ọrịa nwere ụdị ọrịa shuga nke abụọ chọkwara ịgbanye insulin mgbe ọgwụ hypoglycemic ọnụ na-adịghị arụ ọrụ ma ọ bụ na-egbochi ya.Dị ka ọnụ ọgụgụ nke International Federation IDF na 2017 si kwuo, China ugbu a bụ nke mbụ na ọnụ ọgụgụ ndị na-arịa ọrịa shuga, ma ghọọ mba nwere ọrịa shuga na-agbasakarị.Na China, ihe dị ka nde ndị ọrịa 39 na-arịa ọrịa shuga na-adabere ugbu a na injections insulin iji nọgide na-enwe ọkwa shuga dị n'ọbara, mana ihe na-erughị 36.2% nke ndị ọrịa nwere ike nweta njikwa shuga dị mma.Nke a metụtara afọ onye ọrịa, okike, ọkwa agụmakwụkwọ, ọnọdụ akụ na ụba, nnabata ọgwụ, wdg, ma nweekwa mmekọrịta ụfọdụ na usoro nchịkwa.Ọzọkwa, ụfọdụ ndị na-agba insulin na-atụ egwu agịga.
Emepụtara injection subcutaneous na narị afọ nke 19 maka ntụtụ morphine nke subcutaneous iji gwọọ nsogbu ihi ụra.Kemgbe ahụ, usoro ịgba ọgwụ subcutaneous ka na-aga n'ihu na-emeziwanyewanye, ma ọ ka na-akpata mmebi anụ ahụ, nodules subcutaneous, na ọbụna nsogbu dị ka ọrịa, mbufụt ma ọ bụ ikuku embolism.N'afọ ndị 1930, ndị dọkịta America mepụtara sirinji na-enweghị agịga mbụ site n'iji nchọpụta chọpụtara na mmiri mmiri dị na pipeline mmanụ dị elu na-esi na obere oghere dị n'elu pipeline mmanụ ma nwee ike ịbanye n'ime akpụkpọ ahụ wee tinye n'ime mmadụ. ahu.
Ka ọ dị ugbu a, ịgba ọgwụ mgbochi na-enweghị agịga n'ụwa abanyela na ngalaba ịgba ọgwụ mgbochi ọrịa, mgbochi ọrịa na-efe efe, ọgwụgwọ ọgwụ na mpaghara ndị ọzọ.N'afọ 2012, obodo m kwadoro injector nke mbụ na-enweghị agịga insulin TECHIJET nwere ikike ọgụgụ isi nwere onwe ya.A na-ejikarị ya eme ihe na ngalaba ọrịa shuga.A na-akpọkwa ogbugba ogbugba na-enweghị agịga "ntụtụ dị nro".Enweghị mgbu ma nwee ike zere ịfefe ọrịa nke ọma."Tụnyere ntụtụ agịga, ntụtụ na-enweghị agịga agaghị emebi anụ ahụ subcutaneous, zere induration nke ntụtụ ogologo oge na-akpata, ma nwee ike igbochi ndị ọrịa ka ha ghara ịhazi ọgwụgwọ n'ihi egwu nke agịga."Prọfesọ Guo Lixin, onye isi ngalaba nke Endocrinology na Hospitallọ Ọgwụ Beijing, kwuru na ntụtụ na-enweghị agịga nwekwara ike ịzọpụta usoro dị ka ịgbanwe agịga, gbanarị ọrịa na-efe efe, ma belata nsogbu na ọnụ ahịa mkpofu ọgwụ.Ihe a na-akpọ injection na-enweghị agịga bụ ụkpụrụ nke nnukwu ụgbọ elu."Kama agịga nwere nrụgide, jet na-adị oke ngwa ngwa ma nwee ike ịbanye n'ime ahụ. N'ihi na injections na-enweghị agịga nwere ntakịrị mkpasu iwe na njedebe akwara, ha enweghị mmetụta na-egbuke egbuke nke injections ndị na-adabere na agịga na-eme."Prọfesọ Guo Lixin, onye isi ngalaba Endocrinology nke Hospitallọ Ọgwụ Beijing kwuru.N'afọ 2014, ụlọ ọgwụ Beijing na ụlọ ọgwụ Peking Union Medical College jikọrọ ọnụ mere nyocha banyere nnabata insulin na njikwa shuga ọbara nke sirinji na-enweghị agịga na mkpịsị insulin dabere na agịga ọdịnala nwere sirinji na-enweghị agịga dị ka ihe nyocha.Nsonaazụ gosiri na oge kacha elu, njikwa glucose ọbara postprandial, na mgbanwe glucose ọbara postprandial nke insulins na-eme ngwa ngwa na nke na-adịghị adịte aka dị mma karịa nke insulin ịgbanye agịga ọdịnala.E jiri ya tụnyere ịgba ọgwụ mgbochi ọdịnala, ntụtụ na-enweghị agịga na-enye ahụ mmadụ ohere ịmịnye mmiri ọgwụ ngwa ngwa yana karịa n'ihi usoro nchịkwa mgbasa ozi, nke na-enyere aka ịmịnye insulin nke ọma, na-ebelata ụjọ onye ọrịa nke agịga ọdịnala. ogwu ogbugba dabere, ma belata ihe mgbu n'oge ogwu ogwu., si otú ahụ na-eme ka nnabata ndị ọrịa dịkwuo mma, na-eme ka njikwa shuga dị n'ọbara dịkwuo mma, na mgbakwunye na ibelata mmeghachi omume na-adịghị mma nke injection agịga, dị ka nodules subcutaneous, hyperplasia abụba ma ọ bụ atrophy, na ibelata dose injection.
Oge nzipu: Sep-20-2022